HC Wainwright Has Bearish Forecast for EWTX Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Edgewise Therapeutics to a loss of $0.53 per share from $0.50, while maintaining a Buy rating and a $45 price target.
• Edgewise reported a Q3 loss of $0.53 per share, missing the $0.47 consensus estimate by $0.06. Analysts nonetheless hold a Moderate Buy consensus rating with an average target price of $48.75.
• The stock opened at $43.52 and remains near its 12-month high of $48.40, with a market capitalization of approximately $4.73 billion; insider Alan J. Russell recently sold 200,000 shares for about $7.9 million.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Edgewise Therapeutics in a report issued on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will post earnings per share of ($0.53) for the quarter, down from their prior estimate of ($0.50). HC Wainwright currently has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Edgewise Therapeutics' Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($1.24) EPS.

Other equities analysts also recently issued research reports about the company. Guggenheim increased their price target on Edgewise Therapeutics from $41.00 to $51.00 and gave the stock a "buy" rating in a research report on Monday, July 6th. Raymond James Financial restated a "strong-buy" rating and issued a $66.00 price objective on shares of Edgewise Therapeutics in a report on Monday, June 1st. Wedbush upped their price objective on shares of Edgewise Therapeutics from $46.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 1st. Royal Bank Of Canada increased their target price on shares of Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an "outperform" rating in a report on Wednesday, June 17th. Finally, Truist Financial set a $52.00 target price on shares of Edgewise Therapeutics in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $48.75.

Edgewise Therapeutics Stock Performance

NASDAQ EWTX opened at $43.52 on Monday. Edgewise Therapeutics has a 12 month low of $12.30 and a 12 month high of $48.40. The company's 50-day moving average price is $39.45 and its 200-day moving average price is $34.13. The stock has a market cap of $4.73 billion, a PE ratio of -23.52 and a beta of 0.30.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.06).

Insider Transactions at Edgewise Therapeutics

In other Edgewise Therapeutics news, insider Alan J. Russell sold 200,000 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the sale, the insider owned 24,555 shares in the company, valued at approximately $967,712.55. The trade was a 89.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 21.30% of the company's stock.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of large investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its holdings in shares of Edgewise Therapeutics by 64.9% during the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock valued at $33,000 after acquiring an additional 406 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Edgewise Therapeutics in the second quarter worth approximately $45,000. Jones Financial Companies Lllp purchased a new stake in shares of Edgewise Therapeutics during the first quarter worth approximately $47,000. KBC Group NV purchased a new stake in shares of Edgewise Therapeutics during the first quarter worth approximately $49,000. Finally, Seven Fleet Capital Management LP acquired a new position in Edgewise Therapeutics in the 4th quarter valued at $50,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source